Clinical Instrumental Evaluation of the Efficacy of a Dietary Supplement Claiming Anti Hair Loss Properties
Phase: NA
Conditions: Androgenetic Alopecia (AGA), Chronic Telogen Effluvium
Sponsor: Lacer S.A.

 
 
 
“CLINICAL-INSTRUMENTAL EVALUATION OF THE EFFICACY OF A DIETARY 
SUPPLEMENT 
CLAIMING 
ANTIHAIR 
LOSS 
PROPERTIES 
Double-blind, 
randomized, placebo-controlled, multicentric study”. 
 
 
Protocol ID: IT0006736/24 
Date: 06Dec2024 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
Study synopsis 
 
The study is aimed to assess the eﬃcacy of a dietary supplement in two different 
formulations (capsules and drinkable supplements) claimed to reduce hair loss 
in female and male subjects showing androgenetic alopecia (AGA) or chronic 
telogen eﬄuvium. 
In order to reach this goal a randomized, double-blind, parallel groups, placebo-
controlled study was carried out on 240 (264 enrolled) healthy female and male 
subjects included according to speciﬁc inclusion and non-inclusion criteria. In 
particular, male and female subjects aged between 18 and 62 years old, including 
at least 70% of female subjects aged over 30 years old. 50% of the subjects 
showed chronic telogen eﬄuvium and 50% of subjects showed androgenetic 
alopecia (AGA). As per randomization list the subjects were assigned to one of 
the following study groups: dietary supplement capsule, dietary supplement 
capsule placebo, dietary supplement drinkable and dietary supplement drinkable 
placebo. The subjects used assigned product once a day during 6 months with 
safety and eﬃcacy evaluations at baseline, 3 months (3M) and 6 months (6M) of 
product use. The study was approved by an independent ethics committee.